Real-World Experience of Ritlecitinib for the Treatment of Alopecia Areata from an Alopecia Clinic in a Large Tertiary Dermatology Centre
June 2026
in “
British Journal of Dermatology
”
Studysummary This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on academic.oup.com →